Aravind Ravi Kumar

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma.

Olfat Kamel Hasan, Aravind S Ravi Kumar, Grace Kong, Kira Oleinikov, Simona Ben-Haim, Simona Grozinsky-Glasberg, Rodney J Hicks

Journal article  |  2020  |  Journal of Nuclear Medicine

Esthesioneuroblastoma is rare, with limited therapeutic options when unresectable or metastatic; however, expression of somatostat..

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar, Amir Iravani, Grace Kong, Tim Akhurst, Sue Ping Thang, Declan G Murphy, Scott Williams, Michael S Hofman

Journal article  |  2020  |  European Journal of Nuclear Medicine and Molecular Imaging

PURPOSE: We analysed quantitative biomarkers derived from both baseline whole-body imaging and blood serum to identify prognostic ..

Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer

Aravind S Ravi Kumar, Nathan Lawrentschuk, Michael S Hofman

Journal article  |  2020  |  Current Opinion in Urology

PURPOSE OF REVIEW: Molecular imaging with PET/CT targeting the prostate-specific membrane antigen (PSMA) receptor is increasingly ..

Tumour biology characterisation by imaging in clinic

AS Ravi Kumar, WP Law, C Wilson, S Siva, MS Hofman

Book Chapter  |  2020  |  Medical Radiology

There have been advances in multiple imaging modalities in recent decades which allow more sophisticated and non-invasive means of..

Mechanistic Insights for Optimizing PSMA Radioligand Therapy

Aravind S Ravi Kumar, Michael S Hofman

Journal article  |  2020  |  Clinical Cancer Research

PSMA radioligand therapy is a promising new class of therapy for prostate cancer. Heterogeneity of PSMA expression is an important..

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-177-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Thang Sue-Ping, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David Pattison, Alexis Beaulieu, Jennifer Mooi, Ben Tran, Christina Guo, Victor Kalff, Declan G Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott G Williams, Rod J Hicks, et al.

Journal article  |  2020  |  Journal of Nuclear Medicine

177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation ..

The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions

Joseph C Lee, Gemma F Hartnett, Aravind S Ravi Kumar

Journal article  |  2020  |  European Journal of Nuclear Medicine and Molecular Imaging

Setting the stage: Contemporary staging of non-melanomatous skin cancer and implementation of the new American Joint Committee on cancer eighth edition staging manual

Georgina Casswell, Karda Cavanagh, Aravind S Ravi Kumar, Charles Giddings, Lachlan McDowell

Journal article  |  2019  |  Oral Oncology

Non-melanomatous skin cancer (NMSC) generally refers to basal cell and squamous cell carcinoma of the skin. The majority of patien..

The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma

Grace Kong, Tess Schenberg, Christopher J Yates, Alison Trainer, Nirupa Sachithanandan, Amir Iravani, Aravind Ravi Kumar, Michael S Hofman, Tim Akhurst, Michael Michael, Rodney J Hicks

Journal article  |  2019  |  The Journal of Clinical Endocrinology & Metabolism

Purpose: Germline succinate dehydrogenase (SDHx) mutation carriers, especially SDHB, are at increased risk for malignancy and requ..

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

Sue Ping Thang, John Violet, Shahneen Sandhu, Amir Iravani, Tim Akhurst, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Scott G Williams, Rodney J Hicks, Michael S Hofman

Journal article  |  2019  |  European Urology Oncology

BACKGROUND: Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant prostate cancer (mCRPC) ..